ritter.jpg
Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
November 06, 2018 07:00 ET | Ritter Pharmaceuticals, Inc.
Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial  for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019...
ritter.jpg
Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting
October 09, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
ritter.jpg
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
June 27, 2018 07:05 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
ritter.jpg
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
June 27, 2018 07:00 ET | Ritter Pharmaceuticals, Inc.
 Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
ritter.jpg
Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018
June 05, 2018 08:30 ET | Ritter Pharmaceuticals, Inc.
Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter...
ritter.jpg
Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates
May 15, 2018 16:10 ET | Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
March 01, 2018 16:20 ET | Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Qualigen Therapeutics, Inc. - LOGO.jpg
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
October 03, 2017 12:00 ET | Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Stanford Study on Raw Milk Digestibility: Conflicting Interpretations
March 26, 2014 11:37 ET | Weston A. Price Foundation
Washington, DC, March 26, 2014 (GLOBE NEWSWIRE) -- Researchers found little difference between the digestibility of raw versus pasteurized milk, according to a Stanford University study published in...